# A Relative Bioavailability Study of Bupropion Extended-Released 150 mg Tablets Under Fed Conditions

> **NCT00865371** · PHASE1 · COMPLETED · sponsor: **Actavis Inc.** · enrollment: 26 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Abrika Bupropion 150 mg Extended-Released Tablet
- **DRUG:** Wellbutrin SR® 150 mg Extended-Release Tablet, single dose

## Key facts

- **NCT ID:** NCT00865371
- **Lead sponsor:** Actavis Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-09
- **Primary completion:** 2004-09
- **Final completion:** 2004-09
- **Target enrollment:** 26 (ACTUAL)
- **Last updated:** 2010-08-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00865371

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00865371, "A Relative Bioavailability Study of Bupropion Extended-Released 150 mg Tablets Under Fed Conditions". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT00865371. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*